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Abstract
Background: Mesenchymal stem cells (MSCs) are pluripotent stem cells derived from bone marrow with secretory 
functions of various neurotrophic factors. Stromal cell-derived factor-1α (SDF-1α) is also reported as one of chemokines 
released from MSCs. In this research, the therapeutic effects of MSCs through SDF-1α were explored. 6-
hydroxydopamine (6-OHDA, 20 μg) was injected into the right striatum of female SD rats with subsequent 
administration of GFP-labeled MSCs, fibroblasts, (i.v., 1 × 107 cells, respectively) or PBS at 2 hours after 6-OHDA injection. 
All rats were evaluated behaviorally with cylinder test and amphetamine-induced rotation test for 1 month with 
consequent euthanasia for immunohistochemical evaluations. Additionally, to explore the underlying mechanisms, 
neuroprotective effects of SDF-1α were explored using 6-OHDA-exposed PC12 cells by using dopamine (DA) assay and 
TdT-mediated dUTP-biotin nick-end labeling (TUNEL) staining.
Results: Rats receiving MSC transplantation significantly ameliorated behaviorally both in cylinder test and 
amphetamine-induced rotation test compared with the control groups. Correspondingly, rats with MSCs displayed 
significant preservation in the density of tyrosine hydroxylase (TH)-positive fibers in the striatum and the number of 
TH-positive neurons in the substantia nigra pars compacta (SNc) compared to that of control rats. In the in vitro study, 
SDF-1α treatment increased DA release and suppressed cell death induced by 6-OHDA administration compared with 
the control groups.
Conclusions: Consequently, MSC transplantation might exert neuroprotection on 6-OHDA-exposed dopaminergic 
neurons at least partly through anti-apoptotic effects of SDF-1α. The results demonstrate the potentials of intravenous 
MSC administration for clinical applications, although further explorations are required.
Background
Parkinson's disease (PD) is a common neurological disor-
der characterized by degeneration of nigrostriatal dop-
aminergic neurons [1]. The neuronal loss leads to
deficiency of DA in the striatum, which is responsible for
characteristic motor symptoms such as akinesia, rigidity
and tremor [2,3]. The medication using L-DOPA and sur-
gical treatment such as deep brain stimulation are estab-
lished as effective therapies, although those treatments
might not repair the dopaminergic pathway or prevent its
degeneration [4-6].
Cell therapy was developed as a hopeful therapeutic
tool for PD. Neural stem cells [7,8], neural precursor cells
[9], fetal cells [10,11] and embryonic stem cells [12] have
been studied for treatment on PD model of rats. How-
ever, there are ethical problems about the usage of
embryonic and fetal tissues. These cells are limited in
availability and relatively difficult to be prepared. Adult
mesenchymal stem cells (MSCs) have many advantages
for cell therapy because of the easy availability and pluri-
potency without ethical problems [13,14].
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Several cytokines are known to secrete from MSCs.
SDF-1α is one of the chemotactic cytokines (chemokines)
and the unique ligand for a CXC chemokine receptor
(CXCR4) [15]. The chemokines induced by inflammation
in the central nervous system (CNS) usually play a role in
the local immune response. Meanwhile, recent studies
showed that the central functions of chemokines are not
restricted to neuroinflammation, as originally thought,
but extend to novel functions [16-19]. SDF-1α was found
to exert neuroprotective effects [20]. It suppressed cell
loss of primary cortical cultures induced by H2O2 neuro-
toxicity with the modulation of neurotrophic factor-
expression. Rats receiving intracerebral administration of
SDF-1α reduced infarct volumes with functional amelio-
ration through up-regulation of anti-apoptotic proteins
[20].
Recent studies reported that intrastriatal transplanta-
tion of MSCs restored the function of nigrostriatal dop-
aminergic systems, leading to the early improvement of
behavioral deterioration in PD model of rats [21-24].
However, there is no study that demonstrated therapeutic
effects of intravenous MSC administration for PD model
of rats. Furthermore, the mechanisms of functional
recovery achieved by MSCs transplantation have not
been revealed completely so far. In this study, we explored
whether intravenous administration of MSCs exerted
therapeutic effects on PD model of rats in vivo. Then,
neuroprotective effects of SDF-1α secreted from trans-
planted MSCs were explored using 6-OHDA-exposed
PC12 cells in vitro.
Results
In vivo study
Behavioral tests
In cylinder test (Figure 1A), MSC group significantly
ameliorated forelimb akinesia over time, compared to
PBS and fibroblast group (PBS: 44.2 ± 11.3, 46.9 ± 16.6,
53.1 ± 13.3 and 64.7 ± 17.3%; fibroblast: 44.9 ± 14.8, 51.9
± 6.3, 55.0 ± 12.4 and 60.2 ± 16.1%; MSC: 37.1 ± 12.5, 38.5
± 12.6, 33.0 ± 8.9 and 29.3 ± 13.7% at 1, 2, 3 and 4 weeks
after transplantation, respectively. One-way measures of
ANOVA, F2, 16 = 16.2, p < 0.0001 and post-hoc t-test of p's
value < 0.01 vs. other control groups).
In amphetamine-induced rotation test (Figure 1B),
MSC group significantly reduced the number of rotations
over time, compared to PBS and fibroblast group (PBS:
7.5 ± 1.2, 8.8 ± 3.1 and 8.5 ± 3.5 turns/minute; fibroblast:
6.8 ± 1.2, 7.8 ± 2.7 and 8.2 ± 3.3 turns/minute; MSC: 4.2 ±
1.8, 1.6 ± 1.1 and 1.2 ± 0.7 turns/minute at 2, 3 and 4
weeks after transplantation, respectively. One-way mea-
sures of ANOVA, F2, 16 = 15.8, p < 0.0001 and post-hoc t-
test of p's value < 0.01 vs. other control groups). Thus, in
the behavioral tests, MSC group ameliorated behavior-
ally, compared to fibroblast and PBS group with signifi-
cant differences.
TH Immunohistochemical staining in the striatum and SNc
TH staining revealed the significant preservation of TH-
positive fibers in the striatum (49.8 ± 14.5%, relative to
the intact side, p values > 0.05, Figure 2A-D, I) and TH-
positive cells in the SNc (57.3 ± 10.3%, relative to the
intact side; p values > 0.01, Figure 2E-H, J) of MSC group,
compared to those of fibroblast group (striatum: 25.2 ±
13.1%, SNc: 25.2 ± 13.1%) and PBS group (striatum: 25.3
± 12.5%, SNc: 25.3 ± 12.5%).
Detection of transplanted MSCs
At 2 days, 1 week and 4 weeks after cell transplantation,
lungs, kidneys and brains were removed. We found that
the majority of cells were localized to the pulmonary tis-
sue and a few cells actually reached the brain and
remained there at 2 days after transplantation (Figure 3A,
C, E). Some cells were also observed in the pulmonary tis-
sue and the brain at 1 week after transplantation (Figure
3B, D, F), there were significantly fewer than those seen at
2 days after transplantation. There were no detectable
GFP-positive cells in the brain at 4 weeks after transplan-
tation.
Figure 1 Improvement in forelimb akinesia and amphetamine-
induced rotations by MSC transplantation. A: Cylinder test revealed 
the amelioration of forelimb akinesia in rats receiving MSC transplanta-
tion, compared with control groups at 3 and 4 weeks after transplanta-
tion. *p < 0.05 versus the control groups. B: The number of rotations 
was significantly less in rats receiving MSC transplantation, compared 
with that in control groups at 2, 3 and 4 weeks after transplantation. *p 
< 0.05 versus the control groups.
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In vitro study
Characterization of MSCs
We characterized MSCs by immunocytochemical investi-
gations. MSCs were positive for matrix receptors, CD44
(93.2 ± 2.1%, Figure 4A) and negative for leukocyte com-
mon antigen, CD45 (3.8 ± 0.52%, Figure 4B).
Secretion of SDF-1α from MSCs
We used ELISA to determine whether SDF-1α was
secreted from the MSCs. Over 6 and 24 hours period in
culture, MSCs secreted 72.0 ± 16 pg/1 × 104 cells/6 hours
and 183.5 ± 142 pg/1 × 104 cells/24 hours of SDF-1α.
CXCR4 staining
CXCR4 staining revealed that normal PC12 cells
expressed CXCR4 (Figure 5A). The expression of CXCR4
was also observed in 6-OHDA-exposed PC12 cells at 1, 6
and 12 hours after 6-OHDA exposure. At 6 hours after 6-
OHDA exposure, the expression of CXCR4 was remark-
ably up-regulated on 6-OHDA-exposed PC12 cells com-
pared with PBS-exposed PC12 cells (Figure 5B-C).
TUNEL staining
Nuclear fragmentation was observed in 6-OHDA-
exposed PC12 cells at 12 hours after 6-OHDA exposure.
The cell viability of PC12 cells was significantly increased
by SDF-1α treatment (Figure 5D-H). Treatment with PBS
showed many TUNEL-positive apoptotic cells (72.5 ±
8.2% relative to the whole cells). Treatment with 1, 10 and
50 ng/ml of SDF-1α significantly reduced apoptotic cell
death (45.3 ± 2.6, 38.5 ± 8.8 and 42.6 ± 7.6%, respectively,
p < 0.05, Figure 5I) compared to treatment with PBS.
There were no significant differences among the different
concentrations of SDF-1α, that is, 1, 10 and 50 ng/ml.
Figure 2 Preservation of dopaminergic systems of 6-OHDA-lesioned rats by MSC transplantation. A-H: TH-positive fibers in the striatum and 
neurons in the SNc of rats that received MSC transplantation were markedly preserved (D, H), compared with rats receiving PBS injection (B, F) and 
fibroblast transplantation (C, G). Normal TH-positive fibers and neurons were recognized in the intact striatum (A) and SNc (E). Scale bar: 100 μm in 
(A)-(D), 200 μm in (E)-(H). I: The density of TH-positive fibers in the striatum was analyzed with a computerized image analysis system. Rats receiving 
MSC transplantation showed a significant preservation in the density of TH-positive fibers in the striatum compared with the control rats. *p < 0.05 
versus the control groups. J: The number of TH-positive neurons in the SNc was counted. The number of TH-positive neurons in the SNc was also 
significantly high, compared with the control rats. *p < 0.05 versus the control groups.
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HPLC analysis
The supernatant containing DA from 6-OHDA-exposed
PC12 cells were analyzed with HPLC. DA release from 6-
OHDA-exposed PC12 cells significantly increased by
treatment with 1, 10 ng/ml of SDF-1α (1056 ± 126 ng/2 ×
105 cells, 958 ± 114 ng/2 × 105 cells, respectively) com-
pared to treatment with PBS (518 ± 150 ng/2 × 105 cells,
Figure 6). There were no significant differences between
the concentrations of 1 and 10 ng/ml of SDF-1α.
Neutralization assay for anti-apoptotic effect of SDF-1α
6-OHDA-exposed PC12 cells treated with SDF-1α or
MSC supernatant showed significant suppression of
apoptosis (26.6 ± 7.9 and 29.4 ± 3.7%, respectively) com-
pared with PC12 cells treated with SDF-1α combined
with anti-SDF-1α antibody, only anti-SDF-1α antibody,
MSC supernatant combined with anti-SDF-1α antibody
and PBS (43.4 ± 8.5, 45.3 ± 12.5, 33.5 ± 2.7 and 40.5 ±
4.7%, respectively, Figure 7). These results suggested that
MSC supernatant exerted anti-apoptotic effects on 6-
OHDA-exposed PC12 cells and SDF-1α antibody blocked
the anti-apoptotic effect of SDF-1α.
Discussion
We carried out intravenous administration of MSCs on
PD model of rats and evaluated its therapeutic effects
focusing on SDF-1α. Rats with MSC transplantation sig-
nificantly ameliorated both in cylinder test and amphet-
amine-induced rotation test, compared with fibroblasts
and PBS group. Correspondingly, rats with MSCs showed
better preservation in the density of TH-positive fibers in
the striatum and the number of TH-positive neurons in
the SNc. To explore the underlying mechanisms, focusing
on SDF-1α, we then proceeded to in vitro studies. In the
in vitro studies, SDF-1α treatment suppressed apoptotic
cell death of 6-OHDA-exposed PC12 cells with conse-
quent increase of DA release from the cells, compared
with the control. Furthermore, anti-SDF-1α antibody
reduced the anti-apoptotic effects of SDF-1α.
Anti-apoptotic effects of SDF-1α
In our present study, we demonstrated SDF-1α had anti-
apoptotic effects against 6-OHDA-exposed PC12 cells in
vitro. PC12 cells expressed CXCR4, an exclusive receptor
of SDF-1α. CXCR4 is a member of G protein-coupled
receptor (GPCR) family. Many studies have shown that
SDF-1α/CXCR4 interaction causes activation of multiple
signal transduction pathways, including phosphati-
dylinositol 3-kinase (PI3K)/Akt signaling pathway which
provides enhanced survival signal and extracellular sig-
nal-regulated kinase (ERK 1/2) signaling pathway which
provides enhanced cell proliferation [29]. A recent report
also demonstrated that SDF-1α treatment reduced apop-
totic cell death of endothelial progenitor cells under
serum deprivation through PI3K/Akt pathway and
decreased caspase-3-activity, an important apoptotic
molecule [30].
In the CNS diseases, intracerebral administration of
SDF-1α (1 μg/μl) exerted neuroprotection on stroke
model of rats with reduced infarct volumes and improve-
ment in neural plasticity. The report showed that SDF-1α
disrupted the downstream of caspase-3 apoptotic signal
in the ischemic penumbra of stroke model of rats with
subsequent cortical neuronal protection [20]. In PD
model of rats, caspase-3 activity is deeply involved in the
apoptosis of dopaminergic neurons induced by 6-OHDA
[31,32]. Therefore SDF-1α might enhance the survival of
dopaminergic neurons through CXCR4, inducing down-
regulation of caspase-3 and activation of PI3/Akt path-
way.
Figure 3 Detection of transplanted MSCs. Transplanted MSCs were 
observed in lung (A), kidney (C) and brain (E) at 2 days after transplan-
tation. Some MSCs were also observed in lung (B), kidney (D) and brain 
(F) at 1 week after transplantation. The insets of panels E and F demon-
strated the highly magnified images of GFP-positive MSCs. Green: GFP-
positive MSCs, Blue: DAPI-positive nuclei. White arrows show trans-
planted GFP-MSCs. Scale bar: 50 μm.
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Figure 4 Characterization of MSCs. MSCs were positive for CD44 
(CD44: red; GFP: green, A) and negative for CD45 (CD45: red; GFP: 
green, B). Scale bar: 50 μm.
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The activation of DA release by SDF-1α treatment
We showed that SDF-1α promoted DA release from 6-
OHDA-exposed PC12 cells. A recent report demon-
strated that CXCR4 was constitutively expressed on dop-
aminergic neurons in the SNc of normal rats and that
SDF-1α could increase secretion of DA from dopaminer-
gic neurons [33]. Thus, the results suggest that SDF-1α
might activate nigrostriatal DA transmission. In our
study, DA release might be increased by the functional
preservation of 6-OHDA-exposed PC12 cells, as well as
the enhanced survival of PC12 cells by SDF-1α, although
the increasing effects on DA release might not depend on
the dose of SDF-1α. Meanwhile, high dose of SDF-1α
might have proapoptotic effects on the cells. Studies on
neuroblastoma cells demonstrated that 10 nM of SDF-1α
induced neuronal apoptosis after 24 hours-incubation by
the activation of signaling pathways involving Src phos-
Figure 5 Anti-apoptotic effects of SDF-1α on 6-OHDA-exposed PC12 cells. A: CXCR4 was expressed in PBS-exposed PC12 cells. Scale bar: 20 μm. 
B, C: At 6 hours after 6-OHDA exposure, the expression of CXCR4 was remarkably up-regulated on 6-OHDA-exposed PC12 cells (C) compared with 
PBS-exposed PC12 cells (B). Scale bar: 100 μm. D-H: TUNEL/DAPI staining revealed that the number of apoptotic cells with green-colored, fragmented 
TUNEL-positive nuclei were reduced in SDF-1α treatment cells (D: 0.1 ng/ml, E: 1 ng/ml, F: 10 ng/ml, G: 50 ng/ml) compared with that of the control 
cells (H). Scale bar: 100 μm. I: SDF-1α treatment significantly reduced the number of TUNEL-positive 6-OHDA-exposed PC12 cells. *p < 0.05 versus the 
control with PBS.
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phorylation [34]. The discrepancy might lie on the differ-
ences of the used dosage, cells and experiment design,
although we should know the fact that SDF-1α has neuro-
protective effects with possible neuronal toxicity at high
dose.
Neuroprotective/neurotrophic effects of MSCs
Recently the therapeutic potentials of MSC transplanta-
tion have been studied in various pathological conditions
of the CNS [35,36]. It have been demonstrated that intra-
venous administration of MSCs increased the expression
of basic fibroblast growth factor (bFGF), suppressed
apoptotic cell death, promoted endogenous cell prolifera-
tion and subsequently achieved functional recovery after
stroke [37]. Additionally, MSCs produce neurotrophic
factors, including vascular endothelial growth factor
(VEGF), glial cell line-derived neurotrophic factor
(GDNF) and brain-derived neurotrophic factor (BDNF),
which are also well known as strong neuroprotectants
[38]. The mechanisms of therapeutic effects of MSCs in
the ischemic brain might include neuroprotective effects
through the secreted neurotrophic factors, effective
angiogenesis for amelioration in the microenvironment
of ischemic penumbra and enhanced neurogenesis with
possible neuronal differentiation of transplanted MSCs
for synapse formation, although the number might be
very low, especially with intravenous administration
[39,40]. MSC transplantation might also exert neuropro-
tective effects on PD model of rats at least partly through
the secreted trophic factors [41].
In our study, fluorescence microscopy revealed no
detectable GFP-positive cells in the brain at 4 weeks after
transplantation. This fact might be supposed from previ-
ous studies demonstrating that there were scant cells in
the brain after intravenous transplantation of MSCs
[39,40], although in our study, transplanted MSCs might
die during the disease progression or lose green fluores-
cence before euthanasia. Nevertheless, MSC transplanta-
tion exerted strong therapeutic effects, which might be
the proof that secreted trophic factors from MSC grafts
might play a key role in the neuroprotective effects in our
study. Additionally, MSCs were transplanted intrave-
nously at 2 hours after 6-OHDA injection. The early
transplantation of MSCs might be the reason of the
strong therapeutic effects with the possibility to counter-
act 6-OHDA toxicity. As shown in the in vitro study, SDF-
1α from MSCs probably contributed to the functional
recovery as well as other trophic factors.
Conclusions
The present data provided evidences that MSCs might
exert neuroprotection for 6-OHDA-exposed dopaminer-
gic neurons both in vitro and in vivo through possibly
with anti-apoptotic mechanisms. The results suggest the
potentials of intravenous MSC administration for PD.
SDF-1α might be at least partly involved in the neuropro-
tective effects. Clinical application of MSC transplanta-
tion for PD patients might be considered, although
further explorations are required.
Methods
In vivo study
Isolation, characterization and labeling of MSCs
We used adult female Sprague-Dawley rats (n = 6, 220-
250 g, Charles River, Japan) according to the approved
Guidelines of the Institutional Animal Care and Use
Committee of Okayama University. Rats were euthanized
by sodium pentobarbital (200 mg/kg) with subsequent
removal of the femoral bones. After flushing of femoral
bone marrow, total nucleated cells were cultured at 2 ×
104 cells/cm2 in DMEM (Gibco, Cergy Pontoise, France)
supplemented with 10% fetal calf serum (Gibco, Cergy
Pontoise, France), 1% (v/v) penicillin/streptomycin
(Gibco, Cergy Pontoise, France). Fibroblasts were also
obtained from rat skin and cultured in same medium.
Cells were cultured at 37°C in a fully humidified atmo-
sphere with 10% CO2. Medium was changed twice a week
until confluence. The MSCs were isolated on the basis of
their ability to adhere to the culture plates. After the sec-
ond passage, expanded MSCs and fibroblast were used
for infection with a fiber-mutant F/RGD adenovirus vec-
tor containing enhanced green fluorescent protein
(EGFP) genes (AxCA-EGFP-F/RGD). Characterization of
MSCs was assessed by immunocytochemical staining.
MSCs were stained with antibodies against CD44, a rep-
resentative marker of mesenchymal stem cells or CD45, a
Figure 7 Blockade of SDF-1α cancelled neuroprotective effects of 
SDF-1α on 6-OHDA-exposed PC12 cells. SDF-1α antibody blocked 
the anti-apoptotic effect of SDF-1α and MSC supernatant exerted neu-
roprotective effects on 6-OHDA-exposed PC12 cells. *p < 0.05 versus 
all the control groups.
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leukocyte common antigen [25,26]. All the stained cells
were finally double stained with DAPI (4',6-diamino-2-
phenylindole, Sigma-Aldrich, Tokyo, Japan).
PD model by intrastriatal injection of 6-hydroxydopamine
Adult female Sprague-Dawley rats weighing 220-250 g (n
= 25, Charles River, kanagawa, Japan) were used for the
experiments. All the rats were anesthetized by intraperi-
toneal injection of sodium pentobarbital (30 mg/kg) and
placed on a stereotaxic apparatus (Narishige, Tokyo,
Japan). The skull was exposed and a burr hole was drilled.
A total of 20 μg of 6-OHDA (4 μl of 6-OHDA dissolved in
saline containing 0.2 mg/ml ascorbic acid; Sigma-Aldrich,
Tokyo, Japan) was administered in the right striatum with
a Hamilton syringe (26 gauge, Hamilton, Massy, France)
at a flow rate of 1 μl/min. Coordinates from the bregma
were: AP = +1.0 mm, ML = +3.0 mm, DV = -5.0 mm. The
syringe was left in place for 5 minutes after injection and
then removed slowly to optimize toxin diffusion.
Intravenous administration of MSCs, fibroblasts or PBS
At 2 hours after 6-OHDA lesion, rats were anesthetized
with 1.5% halothane with oxygen/nitrogen. GFP-labeled
MSCs (n = 6), GFP-labeled fibroblasts (n = 6), (1 × 107
cells, respectively) or PBS (n = 7) were administered to
PD model of rats by injection into the femoral vein.
Behavioral tests
All rats were evaluated behaviorally with cylinder test and
amphetamine-induced rotation test for 1 month.
Forelimb akinesia was analyzed with cylinder test at 1,
2, 3 and 4 weeks after transplantation. Contacts made by
each forepaw with the wall of a clear cylinder (diameter:
20 cm) were counted. The asymmetry score of forelimb
use in wall exploration was calculated as a contralateral
bias, where contralateral bias = [(the number of contacts
with contralateral limb) - (the number of contacts with
ipsilateral limb)]/[(the number of contacts with contralat-
eral limb) + (the number of contacts with ipsilateral
limb)] × 100 [27,28].
Amphetamine-induced rotational behavior was per-
formed at 2, 3 and 4 weeks after transplantation. Rats
were monitored for 90 minutes with a video camera after
intraperitoneal injection of D-amphetamine (3.0 mg/kg,
Dainippon Sumitomo Pharma, Osaka, Japan). Data are
expressed as the number of complete body turns per min-
ute.
Preparation of brain sections
At 4 weeks after transplantation, rats were euthanized
and brains were removed. Coronal sections were cut at 40
μm-thickness with a freezing microtome (-20°C). Immu-
nohistochemical investigations were performed with
consecutive sections of the striatum and SNc.
TH Immunohistochemical staining in the striatum and SNc
TH staining was performed by free-floating methods.
Sections were washed in PBS and incubated in 3% H2O2
in 70% methanol for 10 minutes to block the endogenous
peroxidase activity. After washing in PBS, sections were
incubated in rabbit anti-TH antibody solution (Chemi-
con, CA, 1:1000) with 10% normal goat serum for 18
hours at 4°C. After rinses in PBS, the sections were incu-
bated for 30 minutes in biotin-conjugated donkey anti-
rabbit IgG (Jackson Laboratories, CA, 1:1000) and subse-
quently avidin-peroxidase complex (Vector Laboratories,
CA, 1:200) for 30 minutes. The sections were then treated
with 3,4-diaminobenzidine (Sigma-Aldrich, Tokyo,
Japan) and H2O2, mounted on albumin-coated slides, and
sealed. Stained sections were analyzed with standard
bright field microscopy (Olympus, Tokyo, Japan).
Detection of transplanted MSCs
At 2 days (n = 2), 1 week (n = 2) and 4 weeks (n = 2) after
cell transplantation, rats were euthanized and brains,
lungs and kidneys were removed in order to find where
transplanted MSCs resided. Coronal sections were cut at
40 μm-thickness with a freezing microtome (-20°C). The
sections were incubated with DAPI solution (Sigma-
Aldrich, Tokyo, Japan) for 30 minutes. Finally, stained
sections were analyzed with fluorescence microscopy
(Keyence, Osaka, Japan).
In vitro study
ELISA analysis for SDF-1α secretion
The level of SDF-1α secreted from MSCs was quantified
using ELISA kits (R&D Systems, Minneapolis, MN). 1 ×
104 MSCs were plated in 12-well culture plate (Thermo
Fisher Scientific, Roskilde, Denmark). At 24 hours after
plating for attachment, cells were incubated with Hanks'
Balanced Salt Solutions (HBSS). Each 50 μl of the super-
natant was obtained 6 and 24 hours later. This ELISA sys-
tem can detect a minimum of 14 pg/ml of SDF-1α.
Culture of PC12 Cells
PC12 cells were obtained from Dainippon Sumitomo
Pharma Biomedical (Osaka, Japan) and used for in vitro
studies. Cells were plated in DMEM supplemented with
5% horse serum (Gibco, Cergy Pontoise, France), 5% new-
born calf serum (Gibco, Cergy Pontoise, France), 1% (v/v)
penicillin/streptomycin (Gibco, Cergy Pontoise, France) a
density of 1 × 105 cells/well on poly-D-ornitin-coated
glass slides in 24-well culture plate (Thermo Fisher Scien-
tific, Roskilde, Denmark). Cells were cultured at 37°C in a
fully humidified atmosphere with 5% CO2. At 24 hours
after the initial plating, the medium was exchanged for
fresh medium.
Addition of SDF-1α and 6-OHDA to PC12 cells
Human recombinant SDF-1α (Peprotech, NJ) was dis-
solved in PBS. PC12 cells were treated with each concen-
tration of SDF-1α (0, 0.1, 1, 10, 50 ng/ml). At 30 minutes
after SDF-1α treatment, cells were exposed to 50 μM 6-
OHDA or PBS for 12 hours at 37°C. Then cells were fixed
with 4% paraformaldehyde for immunocytochemical
investigations. For HPLC analyses, at 12 hours after 6-Wang et al. BMC Neuroscience 2010, 11:52
http://www.biomedcentral.com/1471-2202/11/52
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OHDA exposure, cells were washed by HBSS twice. 500
μl of HBSS were put on each well for 1 hour. The super-
natant was collected, filtered and stored at -80°C.
CXCR4 staining
To confirm the expression of CXCR4 in PC12 cells, we
performed immunocytochemical investigations. At 24
hours after plating for attachment, cells were exposed to
50 μM of 6-OHDA or PBS for 1, 6 and 12 hours at 37°C.
After exposure, cells were fixed with 4% paraformalde-
hyde and incubated in rabbit anti-CXCR4 antibody solu-
tion (Chemicon, MA, 1:1000) with 10% normal goat
serum for 18 hours at 4°C. After rinses in PBS, the sec-
tions were incubated for 30 minutes in FITC-conjugated
donkey anti-rabbit IgG (Jackson Laboratories, CA,
1:1000). Cells were mounted on the slides with GEL/
MOUNT (Biomeda Corporation, CA) and analyzed with
fluorescence microscopy (Olympus, Tokyo, Japan).
TUNEL staining
DNA fragmentation of apoptotic cells were identified by
TUNEL method. The procedure was conducted accord-
ing to the manufacturer's instruction (Roche, Basel, Swit-
zerland). Briefly, PC12 cells were fixed with 4%
paraformaldehyde for 30 minutes and washed in PBS 3
times. Then the cells were incubated with 3% H2O2 in
70% methanol for 10 minutes and washed with PBS twice.
After that, the cells were incubated with 0.1% Triton X-
100 in 0.1% sodium citrate for 2 minutes on ice. The
slides were washed twice with PBS and the areas around
samples were dried. TUNEL reaction mixture (50 μl) was
added to each sample. Subsequently, slides were incu-
bated for 60 minutes at 37°C in a humidified atmosphere
in the dark. After washing with PBS, slides were mounted
by GEL/MOUNT. Stained sections were analyzed with
fluorescence microscopy (Olympus, Tokyo, Japan).
HPLC analysis
DA release from PC12 cells was analyzed by high perfor-
mance liquid chromatography with electrochemical
detection (HPLC-ECD, Shiseido Fine Chemicals, Tokyo,
Japan). Aliquots (200 μl of HBSS) of the supernatant was
injected into HPLC and interphased with an electro-
chemical detector with a glossy carbon flow-through
detector cell. The analytes were separated on a C18, that
is, 5 μm base deactivated reverse-phase column (Shiseido
Fine Chemicals, Tokyo, Japan). The mobile phase with
final pH of 2.5, consisted of 0.1 M NaH2PO4, 150 mg/L
octyl sodium sulfate, 10 mg/L ethylenediamine tetraa-
cetic acid (EDTA) disodium salt, and 5% acetonitrile.
Neutralization of anti-apoptotic effects by SDF-1α using anti-
SDF-1α antibody
We explored whether the neutralization of SDF-1α might
inhibit the anti-apoptotic effects of SDF-1α and superna-
tant of MSC culture might have anti-apoptotic effects on
6-OHDA-exposed PC12 cells. Human recombinant SDF-
1α (Peprotech, NJ, 10 ng/ml) and rabbit anti-SDF-1α anti-
body (Peprotech, NJ, 0.5 μg/ml) were dissolved in PBS,
respectively. Culture supernatant was prepared by har-
vesting MSCs (2 × 105 cells) in HBSS for 24 hours and
diluted 33% to make the dose of SDF-1α appropriate for
the results of previous reports. At 24 hours after plating,
PC12 cells were treated with SDF-1α, SDF-1α combined
with anti-SDF-1α antibody, only anti-SDF-1α antibody,
MSC supernatant, MSC supernatant combined with anti-
SDF-1α antibody and PBS. At 30 minutes after treatment,
cells were exposed to 50 μM 6-OHDA or PBS for 12
hours at 37°C. After exposure, cells were washed 3 times
in PBS and fixed for TUNEL assay.
Statistical analysis
All values were expressed as mean ± standard deviation.
Data were statistically analyzed by one-way measures of
ANOVA. Statistical significance was present at p < 0.05.
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